Classical hematologist; hemostasis/thrombosis, hemophilia, VWD, rare bleeding disorders specialist; severe hemophilia A blood brother🩸, opinions my own
In a recent interview, @JonRob08 of @BloodExpertsIL discusses the findings of a study evaluating joint health status & bleeding phenotype in patients with severe & non-severe #hemophilia A or B using musculoskeletal ultrasound and other clinical tools.🩸
Watch here: 👉 https://t.co/OaF7Y4Udz7
#Hematology #ASH25
Interesting news and was really only a matter of time. Companies should listen to patients, and each individual weigh risks/benefits of all evolving hemophilia therapies. Sometimes patience is the wise approach. #hemophilia#genetherapy
https://t.co/9IaXxlaOyJ
Happy to share our study of recombinant VWF real-world treatment patterns and outcomes at 11 centers in the U.S. We demonstrate that routine rVWF prophylaxis reduced bleed rate and healthcare resource utilization compared to prior VWD treatments. #VWD#VWF https://t.co/vGHiJVMBQg
Proud to work with esteemed colleagues to improve future research priorities. The patient voice, through lived experience experts, must be incorporated into cutting-edge research programs from start to finish. https://t.co/gMQUL70k0C
Honored to receive the Mary Draeger Schultz scholarship 2024 @OSFHealthCare!
Grateful for the opportunity to promote #QI and #PatientSafety in healthcare, and for the incredible support from @UICOMPeoria@UicompP
Honored to receive the Mary Draeger Schultz scholarship 2024 @OSFHealthCare!
Grateful for the opportunity to promote #QI and #PatientSafety in healthcare, and for the incredible support from @UICOMPeoria@UicompP
Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and VWD. https://t.co/x17lE2TNNf This article developed by a global team of 48 experts and international organizations rigorously examines a number of GRADE methodology adaptations.
A critique of the ISTH Haemophilia Guidelines was published in #Haemophilia Journal today with 49 eminent authors representing a global mixture of expertise, all united in their serious concerns about these guidelines which were already outdated on publication 1/3
Here is our just published review in #Blood focusing on how new biological insights into #FVIII
are setting the stage for new #hemophilia therapies.
#hemesky#medsky
https://t.co/ZpAWXNbBEW
With 70% of bleeding events linked to identified or suspected causes, this study highlights the pressing need for better strategies, including long-term VWD factor (VWF) prophylaxis, to reduce hospitalizations and improve quality of life. Read More: https://t.co/IJoEN9Npnu
Centessa have discontinued development of their rebalancing agent, Serpin PC despite encouraging Phase 2 PREScent clinical trial results Decision due to competition from marstacimab and possibly concizumab. This leaves these 2 plus Fitusiran in trials or licenced @ProfMakris